GLPwatch
Papers (10410)
Page 147 of 174, ranked by citation count.
- Unlocking the Potential of Type 2 Diabetes Mellitus Remission.
- Proglucagon-Derived Peptides Do Not Significantly Affect Acute Exocrine Pancreas in Rats.
- GLP-1 receptor agonists in stroke prevention: a narrative review on emerging therapeutic frontiers.
- High BMI z-Scores from Different Growth References Are Not Comparable: An Example from a Weight Management Trial with an Anti-Obesity Medication in Pubertal Adolescents with Obesity.
- [Glucagon-like peptide 1 analogues in the treatment of type 2 diabetes mellitus].
- GLP-1 receptor agonists and smoking cessation: therapeutic promise beyond glycemia.
- Clinical Outcomes of Glucagon-Like Peptide-1 Receptor Agonist (GLP-1 RA) and Glucagon-Like Peptide-1/Glucose-Dependent Insulinotropic Polypeptide Receptor Agonist (GLP-1/GIP RA) Exposures Presenting to the Emergency Department.
- Evaluation of the Short-Term Effect of Tirzepatide on Liver Fibrosis Biomarkers Stratified by the Fibrosis-3 Index (FIB-3) in Patients With Type 2 Diabetes Mellitus.
- Validity and analysis of the Diabetes Injection Device Preference Questionnaire (DID-PQ).
- [(68)Ga-exendin-4 PET-CT for the localization of occult insulinomas: a prospective cohort study].
- The Cascade System of Osmotic Homeostasis Regulation.
- Is there a role for the incretin system in blood pressure regulation?
- FDG-PET/CT-based respiration-gated lung segmentation and quantification of lung inflammation in COPD patients.
- Relationship of early rapid weight loss to efficacy and safety of tirzepatide and semaglutide for obesity: SURMOUNT-5 post hoc analysis.
- Emulated Effects of Glucagon-Like Peptide 1 Receptor Agonist Therapy in the General Population.
- [Effects of exendin-4 on methylglyoxal-induced oxidative stress in PC12 cells].
- Early Adoption and Prescribing Patterns of Resmetirom: A Multi-Institutional National Analysis.
- Treatment With 9-mg Mazdutide for Weight Reduction in Chinese Adults With Obesity: The GLORY-2 Randomized Clinical Trial.
- Efficacy and safety of glucagon-like peptide-1 receptor agonists in Parkinson's disease: a systematic review and meta-analysis of randomized placebo-controlled clinical trials.
- GLP-1 receptor agonists and GIP/GLP-1 co-agonists in the treatment of obesity in adolescents and the elderly.
- Changes to insulin requirements over time with semaglutide in adults with type 1 diabetes on insulin pump therapy: A post-hoc analysis of a double-blinded, randomised, crossover trial.
- Weight management treatment in obesity.
- Effect of Tirzepatide on Heart Failure in Type 2 Diabetes Mellitus and Obesity: A Systematic Review and Meta-Analysis.
- [Pharmacotherapy of obesity in Germany].
- Effects of dipeptidyl peptidase-4 inhibitors in a type 2 diabetes patient with failure of glucagon-like peptide-1 receptor agonists.
- Management of diabetes and pancreatic cancer.
- Can a monthly exenatide extended release regimen provide a therapeutic and cost benefit?
- Weight Loss, Obesity Medication, and Risk of Obesity-Associated Cancer: A Meta-Analysis of Randomized Controlled Trials.
- Impact of oral semaglutide on quality of life and metabolic parameters in patients with type 2 diabetes mellitus: A multicenter observational study.
- Post-semaglutide weight regain in females with obesity: Associations with gut microbiota, bile acid metabolism, and central nervous system.
- [Obesity treatment with liraglutide in a patient with Prader-Willi syndrome: a case report].
- Exosomal miR-450b-5p Secreted from Exendin-4-Stimulated Endothelial Cells Protects Retinal Ganglion Cells Against Ischemia Reperfusion Injury.
- Influence of Combination Therapy with Dulaglutide or Liraglutide and SGLT2 Inhibitors on Renal Outcomes in Patients with Type 2 Diabetes: A Post-hoc Analysis of the RECAP Study.
- Revolutionizing type 2 diabetes management: the role of the pharmacist in unlocking the potential of tirzepatide.
- New therapeutic options: management strategies to optimize glycemic control.
- Patients' Experiences of Obstructive Sleep Apnea and Tirzepatide Treatment: An Exit Interview Study.
- Shifts in body mass index category with tirzepatide and associated changes in cardiometabolic risk factors in people with obesity: a post hoc analysis from the SURMOUNT-1 and SURMOUNT-4 trials.
- Bolus Injection of Liraglutide Raises Plasma Glucose in Normal Rats by Activating Glucagon-like Peptide 1 Receptor in the Brain.
- Med14 phosphorylation shapes genomic response to GLP-1 agonists.
- Recombination and functional studies of a dual-action peptide for diabetes.
- Exenatide for once-weekly administration.
- Semaglutide 2.4 mg in French people living with Class 3 obesity and comorbidities: Baseline characteristics and real-world safety data.
- Comparison of the Continuous Glucose Monitoring Profiles of Four Glucose-Lowering Medications in the GRADE Randomized Trial.
- Endocrinology: What You May Have Missed in 2025.
- Cost-effectiveness of semaglutide 2.4 mg versus liraglutide 3 mg for the treatment of obesity in Greece.
- Preserved pharmacokinetics and pharmacodynamics of insulin degludec and liraglutide when administered as insulin degludec/liraglutide in a Chinese population.
- Effects of exenatide on microvascular reactivity in patients with type 2 diabetes and coronary artery disease: A randomized controlled study.
- Cardiorenal benefits of glucagon-like peptide-1 analogues vs. exendin-4 analogues in patients with type 2 diabetes: a meta-analysis based on cardiovascular outcome trials.
- [Effect of exendin-4 on monocyte chemoattractant protein-1 expression in cultured rat glomerular mesangial cells induced by tumor necrosis factor-α in vitro].
- [Type 2 diabetes mellitus and obesity: should we treat the obesity or the diabetes?].
- Tandem mass tag-based proteomic profiling revealed potential therapeutic targets and mechanisms of liraglutide for the treatment of impaired glucose tolerance.
- Dulaglutide plus dapaglifozin use until the second trimester of pregnancy in a woman with type 2 diabetes.
- GLP-1 receptor agonist exendin-4 suppresses food intake by inhibiting hindbrain orexigenic NPY neurons.
- The Effects of Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists on Polycystic Ovarian Syndrome: A Scoping Review.
- Tirzepatide safety in type 2 diabetes: a disproportionality analysis of adverse events using the FDA FAERS database.
- A Case of Pulmonary Hemorrhage, Supratherapeutic International Normalized Ratio (INR), and Anti-neutrophil Cytoplasmic Antibody (ANCA)-Associated Vasculitis: Unmasking a Potential Link to Tirzepatide.
- Real-world clinical responses in patients with type 2 diabetes mellitus adding exenatide BID (EBID) or mealtime insulin to basal insulin: a retrospective study using electronic medical record data.
- Reply: <sup>68</sup>Ga NODAGA-Exendin-4 PET Scanning for Focal Congenital Hyperinsulinism: Need for Replication.
- Distinguishing among incretin-based therapies. Introduction.
- Apitegromab for lean mass preservation during tirzepatide-induced weight loss: a randomized, double-blind, placebo-controlled phase 2 trial.